Serious adverse events
|
Renal |
Pancreas-Kidney |
Liver |
Heart |
Lung/Heart-Lung |
Pediatric Renal |
Total subjects affected by serious adverse events
|
|
|
|
|
|
|
subjects affected / exposed
|
256 / 701 (36.52%) |
8 / 8 (100.00%) |
9 / 18 (50.00%) |
112 / 254 (44.09%) |
11 / 24 (45.83%) |
7 / 19 (36.84%) |
number of deaths (all causes)
|
24 |
0 |
1 |
20 |
3 |
0 |
number of deaths resulting from adverse events
|
0 |
0 |
0 |
0 |
0 |
0 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
|
|
|
BASAL CELL CARCINOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
4 / 254 (1.57%) |
2 / 24 (8.33%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 2 |
0 / 0 |
0 / 4 |
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BENIGN LUNG NEOPLASM
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BLADDER CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BOWEN'S DISEASE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BREAST CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CERVIX NEOPLASM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
COLON ADENOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ENDOMETRIAL CANCER METASTATIC
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEAD AND NECK CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 701 (0.57%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEPATIC NEOPLASM MALIGNANT
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
INVASIVE DUCTAL BREAST CARCINOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LUNG ADENOCARCINOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MALIGNANT MELANOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
METASTATIC GASTRIC CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
METASTATIC RENAL CELL CARCINOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MYELOPROLIFERATIVE DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NASAL CAVITY CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PROSTATE CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL NEOPLASM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SKIN CANCER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SMALL CELL LUNG CANCER STAGE UNSPECIFIED
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
SOFT TISSUE NEOPLASM
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SQUAMOUS CELL CARCINOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
5 / 254 (1.97%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
0 / 0 |
0 / 8 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SQUAMOUS CELL CARCINOMA OF SKIN
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 5 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
|
|
|
|
AORTIC ANEURYSM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ARTERIAL HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CIRCULATORY COLLAPSE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DEEP VEIN THROMBOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
13 / 701 (1.85%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 14 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIABETIC VASCULAR DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FEMORAL ARTERIAL STENOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HAEMATOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERTENSION
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 701 (0.57%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERTENSIVE CRISIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPOTENSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPOVOLAEMIC SHOCK
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INTERMITTENT CLAUDICATION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LYMPHOCELE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LYMPHOEDEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MALIGNANT HYPERTENSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ORTHOSTATIC HYPOTENSION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERIPHERAL ISCHAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERIPHERAL VASCULAR DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SHOCK
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
THROMBOPHLEBITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
THROMBOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
VENOUS OCCLUSION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Surgical and medical procedures
|
|
|
|
|
|
|
CORONARY ANGIOPLASTY
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEART TRANSPLANT
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PANCREATECTOMY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
|
|
|
|
ADVERSE DRUG REACTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ASTHENIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHEST DISCOMFORT
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DEATH
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
DEVICE MALFUNCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DEVICE OCCLUSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FATIGUE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HERNIA OBSTRUCTIVE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERTHERMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
IMPAIRED HEALING
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MALAISE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MULTI-ORGAN FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
NON-CARDIAC CHEST PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OEDEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OEDEMA PERIPHERAL
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 701 (0.57%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 1 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PYREXIA
|
|
|
|
|
|
|
subjects affected / exposed
|
16 / 701 (2.28%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
4 / 254 (1.57%) |
1 / 24 (4.17%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 17 |
0 / 1 |
0 / 0 |
0 / 4 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SUDDEN CARDIAC DEATH
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune system disorders
|
|
|
|
|
|
|
ALLERGIC OEDEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ANAPHYLACTIC REACTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DRUG HYPERSENSITIVITY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEART TRANSPLANT REJECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
KIDNEY TRANSPLANT REJECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TRANSPLANT REJECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
6 / 254 (2.36%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 0 |
0 / 0 |
0 / 8 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Social circumstances
|
|
|
|
|
|
|
ABORTED PREGNANCY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PREGNANCY OF PARTNER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
|
|
|
|
ENDOMETRIOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OVARIAN CYST
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PROSTATOMEGALY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
|
|
|
ACUTE RESPIRATORY DISTRESS SYNDROME
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ACUTE RESPIRATORY FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ALVEOLITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ATELECTASIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BRONCHIAL HYPERREACTIVITY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BRONCHOSPASM
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
COUGH
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIAPHRAGMATIC HERNIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DYSPNOEA
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
4 / 254 (1.57%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DYSPNOEA EXERTIONAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
EMPHYSEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
EPISTAXIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPOXIA
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INTERSTITIAL LUNG DISEASE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LUNG DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OROPHARYNGEAL PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PLEURAL EFFUSION
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 701 (0.86%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PLEURITIC PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMOTHORAX
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PRODUCTIVE COUGH
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PULMONARY ALVEOLAR HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PULMONARY EMBOLISM
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
PULMONARY FIBROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PULMONARY HYPERTENSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PULMONARY MASS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PULMONARY OEDEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RESPIRATORY DISTRESS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RESPIRATORY FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
SLEEP APNOEA SYNDROME
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
|
|
|
|
ANXIETY
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CONFUSIONAL STATE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DELIRIUM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MAJOR DEPRESSION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MENTAL STATUS CHANGES
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
1 / 8 (12.50%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Investigations
|
|
|
|
|
|
|
BLEEDING TIME PROLONGED
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BLOOD CREATININE INCREASED
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BLOOD GLUCOSE INCREASED
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CATHETERISATION CARDIAC
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
EJECTION FRACTION DECREASED
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEPATIC ENZYME INCREASED
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LIVER FUNCTION TEST ABNORMAL
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
WEIGHT INCREASED
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
|
|
|
|
ANIMAL SCRATCH
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ANKLE FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BURNS SECOND DEGREE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CERVICAL VERTEBRAL FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHEMICAL POISONING
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHRONIC ALLOGRAFT NEPHROPATHY
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
COMPLICATIONS OF TRANSPLANTED KIDNEY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
COMPLICATIONS OF TRANSPLANTED PANCREAS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FALL
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FEMORAL NECK FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FEMUR FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTROINTESTINAL STOMA COMPLICATION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GRAFT LOSS
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HIP FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INCISIONAL HERNIA
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INCISIONAL HERNIA, OBSTRUCTIVE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LACERATION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LOWER LIMB FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LUNG INJURY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OVERDOSE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PELVIC FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PHARYNGEAL INJURY
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
POST PROCEDURAL HAEMATOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RIB FRACTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ROAD TRAFFIC ACCIDENT
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TENDON RUPTURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TOXICITY TO VARIOUS AGENTS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TRANSPLANT DYSFUNCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TRANSPLANT FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TRAUMATIC HAEMATOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
|
|
|
|
ACUTE CORONARY SYNDROME
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ACUTE MYOCARDIAL INFARCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
8 / 701 (1.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ANGINA PECTORIS
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 701 (0.86%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ARRHYTHMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
ATRIAL FIBRILLATION
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ATRIAL FLUTTER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ATRIAL THROMBOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ATRIOVENTRICULAR BLOCK COMPLETE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CARDIAC ARREST
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CARDIAC FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CARDIAC FAILURE ACUTE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CARDIAC FAILURE CHRONIC
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
CARDIAC FAILURE CONGESTIVE
|
|
|
|
|
|
|
subjects affected / exposed
|
10 / 701 (1.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CARDIO-RESPIRATORY ARREST
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
CARDIOGENIC SHOCK
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CORONARY ARTERY DISEASE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CORONARY ARTERY INSUFFICIENCY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CORONARY ARTERY OCCLUSION
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
LEFT VENTRICULAR DYSFUNCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MYOCARDIAL INFARCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MYOCARDIAL ISCHAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PALPITATIONS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERICARDIAL EFFUSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PULSELESS ELECTRICAL ACTIVITY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SICK SINUS SYNDROME
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SINOATRIAL BLOCK
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
STRESS CARDIOMYOPATHY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SUPRAVENTRICULAR TACHYCARDIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TRICUSPID VALVE INCOMPETENCE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
VENTRICULAR TACHYCARDIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nervous system disorders
|
|
|
|
|
|
|
CEREBRAL DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CEREBRAL HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CEREBRAL INFARCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CEREBRAL ISCHAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
CEREBROVASCULAR ACCIDENT
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIZZINESS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FEBRILE CONVULSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HAEMORRHAGIC STROKE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEADACHE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEMIPARESIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INTRACRANIAL ANEURYSM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ISCHAEMIC CEREBRAL INFARCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LUMBAR RADICULOPATHY
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MYOCLONUS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NEUROPATHY PERIPHERAL
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PRESYNCOPE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SUBARACHNOID HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SYNCOPE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TRANSIENT ISCHAEMIC ATTACK
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
|
|
|
|
ANAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
7 / 254 (2.76%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 7 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ANAEMIA OF CHRONIC DISEASE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HAEMOLYTIC ANAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
IRON DEFICIENCY ANAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LYMPHADENITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MICROCYTIC ANAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NEUTROPENIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PANCYTOPENIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SPLENIC VEIN THROMBOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SPONTANEOUS HAEMATOMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
THROMBOCYTOPENIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
|
|
|
|
ABDOMINAL ADHESIONS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABDOMINAL DISTENSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABDOMINAL HERNIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
5 / 254 (1.97%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABDOMINAL HERNIA OBSTRUCTIVE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABDOMINAL MASS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABDOMINAL PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
4 / 254 (1.57%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABDOMINAL PAIN UPPER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ASCITES
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CONSTIPATION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIABETIC GASTROPARESIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIAPHRAGMATIC HERNIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIARRHOEA
|
|
|
|
|
|
|
subjects affected / exposed
|
9 / 701 (1.28%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIEULAFOY'S VASCULAR MALFORMATION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DYSPEPSIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FOOD POISONING
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTRIC ULCER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTRITIS EROSIVE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTROINTESTINAL HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTROINTESTINAL NECROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ILEUS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INGUINAL HERNIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INTESTINAL ISCHAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INTESTINAL OBSTRUCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LARGE INTESTINAL OBSTRUCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NAUSEA
|
|
|
|
|
|
|
subjects affected / exposed
|
11 / 701 (1.57%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OESOPHAGEAL ULCER
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PANCREATIC DUCT DILATATION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PANCREATITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PANCREATITIS ACUTE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PEPTIC ULCER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMOPERITONEUM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RETROPERITONEAL HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SMALL INTESTINAL OBSTRUCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
UPPER GASTROINTESTINAL HAEMORRHAGE
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
VOMITING
|
|
|
|
|
|
|
subjects affected / exposed
|
9 / 701 (1.28%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
5 / 254 (1.97%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 0 |
0 / 0 |
0 / 6 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
|
|
|
|
BILE DUCT STONE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BILIARY COLIC
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHOLANGIOLITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHOLANGITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
2 / 18 (11.11%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHOLECYSTITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHOLECYSTITIS ACUTE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHOLELITHIASIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GALLBLADDER DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEPATIC CYST
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEPATIC FIBROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEPATIC FUNCTION ABNORMAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ISCHAEMIC HEPATITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
JAUNDICE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LIVER DISORDER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
|
|
|
|
ANGIOEDEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIABETIC ULCER
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ERYTHEMA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ERYTHEMA NODOSUM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERHIDROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SKIN LESION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SKIN ULCER
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
|
|
|
|
ACUTE PRERENAL FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
AZOTAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FOCAL SEGMENTAL GLOMERULOSCLEROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HAEMATURIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYDRONEPHROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
IGA NEPHROPATHY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NEPHROLITHIASIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NEPHROPATHY TOXIC
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OBSTRUCTIVE UROPATHY
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PROTEINURIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PYELOCALIECTASIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL ARTERY STENOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL COLIC
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL FAILURE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL FAILURE ACUTE
|
|
|
|
|
|
|
subjects affected / exposed
|
21 / 701 (3.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
7 / 254 (2.76%) |
2 / 24 (8.33%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 23 |
0 / 1 |
0 / 0 |
0 / 8 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL FAILURE CHRONIC
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
5 / 254 (1.97%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
RENAL IMPAIRMENT
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 701 (0.86%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RENAL INSUFFICIENCY
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
6 / 254 (2.36%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 6 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
URETERIC OBSTRUCTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
|
|
|
|
HYPERPARATHYROIDISM
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
|
|
|
|
ARTHRALGIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ARTHRITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BACK PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BURSITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GOUTY ARTHRITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INTERVERTEBRAL DISC PROTRUSION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MONARTHRITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MUSCULAR WEAKNESS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MUSCULOSKELETAL CHEST PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MUSCULOSKELETAL PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MYALGIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NEUROPATHIC ARTHROPATHY
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OSTEOARTHRITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OSTEONECROSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERIOSTITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RHABDOMYOLYSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SPINAL PAIN
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
TENDONITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
|
|
|
|
ABDOMINAL ABSCESS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABSCESS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ABSCESS LIMB
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
APPENDICITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
APPENDICITIS PERFORATED
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ARTERIOVENOUS GRAFT SITE INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BACTERAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
1 / 8 (12.50%) |
1 / 18 (5.56%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BACTERIAL PYELONEPHRITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BACTERIAL SEPSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BK VIRUS INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BRONCHITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BRONCHOPNEUMONIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
BRONCHOPULMONARY ASPERGILLOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CANDIDA INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CATHETER SITE CELLULITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CELLULITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
8 / 701 (1.14%) |
1 / 8 (12.50%) |
1 / 18 (5.56%) |
5 / 254 (1.97%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 1 |
0 / 1 |
0 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CHRONIC SINUSITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CLOSTRIDIUM DIFFICILE COLITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CLOSTRIDIUM DIFFICILE INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CLOSTRIDIUM DIFFICILE SEPSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CYSTITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CYTOMEGALOVIRUS INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
CYTOMEGALOVIRUS OESOPHAGITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DEVICE RELATED INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIVERTICULITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
EPSTEIN-BARR VIRUS INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ESCHERICHIA BACTERAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FEBRILE INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTROENTERITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
10 / 701 (1.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GASTROENTERITIS VIRAL
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 701 (0.57%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HEPATITIS B
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HERPES ZOSTER
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HUMAN EHRLICHIOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INCISION SITE CELLULITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INFECTED LYMPHOCELE
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
INFLUENZA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
JC VIRUS INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
JOINT ABSCESS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
KLEBSIELLA INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LIVER ABSCESS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LOBAR PNEUMONIA
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 701 (0.71%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LOCALISED INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LOWER RESPIRATORY TRACT INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
LUNG INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
MENINGITIS PNEUMOCOCCAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NASOPHARYNGITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
NOSOCOMIAL INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
ORAL CANDIDIASIS
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OSTEOMYELITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
OTITIS MEDIA BACTERIAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERIRECTAL ABSCESS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PERITONITIS BACTERIAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMOCYSTIS JIROVECII PNEUMONIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA
|
|
|
|
|
|
|
subjects affected / exposed
|
31 / 701 (4.42%) |
1 / 8 (12.50%) |
1 / 18 (5.56%) |
7 / 254 (2.76%) |
5 / 24 (20.83%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 34 |
0 / 1 |
0 / 1 |
0 / 7 |
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
PNEUMONIA BORDETELLA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA KLEBSIELLA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA LEGIONELLA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA PRIMARY ATYPICAL
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA PSEUDOMONAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA STREPTOCOCCAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PNEUMONIA VIRAL
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
POSTOPERATIVE WOUND INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PYELONEPHRITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
8 / 701 (1.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
PYELONEPHRITIS ACUTE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
RESPIRATORY TRACT INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SEPSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SEPTIC SHOCK
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 701 (0.57%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SINUSITIS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
2 / 19 (10.53%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SKIN INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
STAPHYLOCOCCAL BACTERAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
STREPTOCOCCAL INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
STREPTOCOCCAL SEPSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
SUBCUTANEOUS ABSCESS
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
UPPER RESPIRATORY TRACT INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
2 / 24 (8.33%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
URINARY TRACT INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
20 / 701 (2.85%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
3 / 254 (1.18%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 24 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
UROSEPSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 701 (1.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
VIRAL DIARRHOEA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
VIRAL INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
VIRAL UPPER RESPIRATORY TRACT INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
WOUND INFECTION
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
WOUND INFECTION STAPHYLOCOCCAL
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
0 / 8 (0.00%) |
1 / 18 (5.56%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metabolism and nutrition disorders
|
|
|
|
|
|
|
DECREASED APPETITE
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DEHYDRATION
|
|
|
|
|
|
|
subjects affected / exposed
|
9 / 701 (1.28%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
2 / 254 (0.79%) |
0 / 24 (0.00%) |
1 / 19 (5.26%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 1 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIABETES MELLITUS
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIABETIC FOOT
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
DIABETIC KETOACIDOSIS
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 701 (0.57%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
FLUID OVERLOAD
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
GOUT
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERGLYCAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 701 (0.43%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
1 / 24 (4.17%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERKALAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 701 (0.00%) |
1 / 8 (12.50%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPERLIPIDAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPOGLYCAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPOKALAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 701 (0.14%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
0 / 254 (0.00%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPONATRAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
HYPOVOLAEMIA
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 701 (0.29%) |
0 / 8 (0.00%) |
0 / 18 (0.00%) |
1 / 254 (0.39%) |
0 / 24 (0.00%) |
0 / 19 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |